Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1349

1.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

2.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

3.

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Skjøth F, Larsen TB, Rasmussen LH, Lip GY.

Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.

PMID:
24577485
4.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
5.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
6.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

7.

Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.

Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.

Clin Ther. 2013 Jul;35(7):967-984.e2. doi: 10.1016/j.clinthera.2013.05.011.

PMID:
23870607
8.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
9.
10.

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C.

J Thromb Haemost. 2012 Oct;10(10):1979-87. doi: 10.1111/j.1538-7836.2012.04866.x. Review.

11.

Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.

Akwaa F, Spyropoulos AC.

Hosp Pract (1995). 2013 Feb;41(1):8-18. doi: 10.3810/hp.2013.02.1008. Review.

PMID:
23466963
12.

Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.

Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, Oreglia J, Latib A, Pizzocri S, Laudisa ML, Brambilla N, Bedogni F.

QJM. 2012 Oct;105(10):949-57. Epub 2012 Jul 6.

PMID:
22771555
13.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
14.

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

Baker WL, Phung OJ.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):711-9. Epub 2012 Aug 21. Review.

15.

Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.

Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.

Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.

PMID:
26655548
16.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
17.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

18.

Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.

Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.

Int Angiol. 2014 Aug;33(4):301-8. Review.

PMID:
25056161
19.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

20.

Supplemental Content

Support Center